What genetic defects respond to sapropterin?
Sapropterin (a synthetic form of tetrahydrobiopterin, BH4) is used for forms of hyperphenylalaninemia caused by defects in the phenylalanine hydroxylase (PAH) pathway where adding BH4 can restore some enzyme activity. It is most relevant to patients with PAH deficiency who have BH4 responsiveness, and it can also help certain causes that involve impaired BH4 availability or PAH function that improves when BH4 levels rise.
How BH4 helps when phenylalanine hydroxylase is impaired
Phenylalanine hydroxylase requires BH4 to convert phenylalanine into tyrosine. When BH4 is low or the PAH enzyme is only partially functional (so it needs extra support), sapropterin increases available BH4. That can raise phenylalanine hydroxylation and lower blood phenylalanine levels.
In practical terms, sapropterin is treating the underlying metabolic “bottleneck” by boosting a required cofactor rather than replacing the defective enzyme itself.
What happens in patients with BH4-nonresponsive defects
Not every genetic defect in the PAH pathway improves with added BH4. If a patient’s PAH gene defect produces an enzyme variant that cannot work even with extra BH4, sapropterin will not meaningfully correct phenylalanine metabolism. In those cases, treatment typically relies on dietary phenylalanine restriction and other therapies that do not depend on BH4 to fully restore PAH activity.
How clinicians determine whether the defect is likely to respond
Because response depends on how much the specific mutation can benefit from higher BH4 availability, clinicians evaluate BH4 responsiveness. The usual approach is a BH4 loading or responsiveness test with close monitoring of blood phenylalanine during therapy. A fall in phenylalanine suggests the defect is functionally BH4-responsive.
What other PAH-pathway genetic issues does sapropterin target?
Sapropterin is aimed at supporting the same BH4-dependent biochemical step (phenylalanine to tyrosine). So genetic issues that lead to BH4 deficiency or reduced BH4 cofactor function in the pathway can be helped by supplying BH4 directly, because it raises cofactor availability for PAH. If the problem is instead primarily inability of PAH to use BH4 (a truly nonfunctional PAH variant), sapropterin may have limited effect.